Ritchlin < Rituximab < Rituximab administration

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by Rituximab

Number of relevant bibliographic references: 232.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
002528 (2014)	Ann-Sophie Lauenstein [Allemagne] ; Mark Stettner [Allemagne] ; Bernd C. Kieseier [Allemagne] ; Eckart Lensch [Allemagne]	Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab
002833 (2013)	Kristian Thorlund [Canada] ; Eric Druyts [Canada] ; J Antonio Avi A-Zubieta [Canada] ; Ping Wu [Canada] ; Edward J. Mills [Canada]	Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings
002834 (2013)	Daniel E. Furst [États-Unis] ; Edward Clark Keystone [Canada] ; Alexander K. So [États-Unis, Canada, Allemagne, Pays-Bas, Italie, Royaume-Uni, Autriche] ; Jürgen Braun [Allemagne] ; Ferry C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Italie] ; Fabrizio De Benedetti [Allemagne] ; Thomas Dörner [Allemagne] ; Paul Emery [Royaume-Uni] ; Roy Fleischmann [États-Unis] ; Allan Gibofsky [États-Unis] ; J R Kalden [Allemagne] ; Arthur Kavanaugh [États-Unis] ; Bruce Kirkham [Royaume-Uni] ; Philip Mease [États-Unis] ; A. Rubbert-Roth [Allemagne] ; Joachim Sieper [Allemagne] ; Nora G. Singer [États-Unis] ; Josef S. Smolen [Autriche] ; Piet L C M. Van Riel [Pays-Bas] ; Michael H. Weisman [États-Unis] ; Kevin L. Winthrop [États-Unis]	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012
002835 (2013)	Edith Villeneuve [Canada] ; Boulos Haraoui [Canada]	Uncoupling of disease activity and structural damage. Does it matter clinically?
002838 (2013)	Samantha Louise Smith [Royaume-Uni] ; Darren Plant [Royaume-Uni] ; Stephen Eyre [Royaume-Uni] ; Anne Barton [Royaume-Uni]	The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis
002842 (2013)	Daniel Aletaha [Autriche] ; Farideh Alasti [Autriche] ; Josef S. Smolen [Autriche]	Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients
002850 (2013)	In-Ho Song [Allemagne] ; Frank Heldmann [Allemagne] ; Martin Rudwaleit [Allemagne] ; Joachim Listing [Allemagne] ; Heiner Appel [Allemagne] ; Iris Haug-Rost [Allemagne] ; Jürgen Braun [Allemagne] ; Joachim Sieper [Allemagne]	One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare
002868 (2013)	Josef S. Smolen [Autriche] ; Daniel Aletaha [Autriche]	Forget personalised medicine and focus on abating disease activity
002871 (2013)	John D. Isaacs [Royaume-Uni] ; Stanley B. Cohen [États-Unis] ; Paul Emery [Royaume-Uni] ; Paul P. Tak [Pays-Bas, Royaume-Uni] ; Jianmei Wang [Royaume-Uni] ; Guiyuan Lei [Royaume-Uni] ; Sarah Williams [Royaume-Uni] ; Preeti Lal [États-Unis] ; Simon J. Read [Royaume-Uni]	Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis
002872 (2013)	Daniel E. Furst [États-Unis] ; Roy Fleischman [États-Unis] ; Joachim Kalden [États-Unis] ; Arthur Kavanaugh [États-Unis] ; Joachim Sieper [États-Unis] ; Philip Mease [États-Unis] ; Josef Smolen [États-Unis] ; Ferrie Breedveld [États-Unis]	Documentation of off-label use of biologics in Rheumatoid Arthritis
002874 (2013)	Josef S. Smolen [Autriche] ; Monika M. Schoels [Autriche] ; Norihiro Nishimoto [Japon] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino [Espagne] ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho Murakami [Japon] ; Neil Betteridge [Royaume-Uni] ; Clifton O. Bingham [États-Unis] ; Vivian Bykerk [Suisse] ; Ernest H. Choy [Royaume-Uni] ; Bernard Combe [France] ; Maurizio Cutolo [Italie] ; Winfried Graninger [Autriche] ; Angel Lanas [Espagne] ; Emilio Martin-Mola [Espagne] ; Carlomaurizio Montecucco [Italie] ; Mikkel Ostergaard [Danemark] ; Karel Pavelka [République tchèque] ; Andrea Rubbert-Roth [Allemagne] ; Naveed Sattar [Royaume-Uni] ; Marieke Scholte-Voshaar [Suisse] ; Yoshiya Tanaka [Japon] ; Michael Trauner [Autriche] ; Gabriele Valentini [Italie] ; Kevin L. Winthrop [États-Unis] ; Maarten De Wit [Pays-Bas] ; Désirée Van Der Heijde [Pays-Bas]	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
002879 (2013)	Paul Emery [Royaume-Uni] ; Anthony Sebba [États-Unis] ; Tom W J. Huizinga [Pays-Bas]	Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
002894 (2013)	Oliver Foot ; Anshuman Malaviya	Treatment of rheumatoid arthritis: current and future
002905 (2013)		The 24th Annual Meeting of Japanese Society of Neuroimmunology (JSNI)
002952 (2013)	N. Stein [Allemagne] ; M. Witt [Allemagne] ; M. Baeuerle [Allemagne] ; H. Schulze-Koops [Allemagne] ; M. Gruenke [Allemagne]	THU0400 Inhibition of IL-6 signalling: A novel therapeutic approach for familial mediterranean fever
002953 (2013)	M. Ozmen ; V. Kurtoglu [Turquie] ; G. Can ; E. F. Tarhan ; D. Soysal [Turquie] ; S. L. Aslan [Turquie]	THU0399 Is pernio a microvascular disease?
002954 (2013)	M. Yamamoto ; H. Takahashi ; Y. Naishiro ; T. Tabeya ; K. Ishigami ; Y. Shimizu ; H. Yajima ; M. Matsui ; C. Suzuki ; H. Yamamoto ; S. Honda ; T. Abe ; Y. Suzuki ; T. Himi ; K. Imai [Japon] ; Y. Shinomura	THU0398 Efficacy of rituximab and other immunosuppressants for IgG4-related disease
002996 (2013)	D. Isenberg [Royaume-Uni] ; C. Gordon [Royaume-Uni] ; D. Licu [Suisse] ; S. Copt [Suisse] ; C. Pena Rossi [Suisse] ; D. Wofsy [États-Unis]	THU0276 Efficacy and Safety of Atacicept for Prevention of Flares in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): 52-wk Data (April-SLE Trial)
002A27 (2013)	T. Kojima ; K. Funahashi ; N. Takahashi ; D. Kato ; H. Matsubara ; Y. Hattori ; Y. Yabe [Japon] ; N. Ishiguro	THU0124 Importance of monitoring of C-reactive protein level to predict achievement of better clinical outcome during treatment with tocilizumab in patients with rheumatoid arthritis
002A28 (2013)	S. Das [Royaume-Uni] ; M. Fernandez Matilla [Espagne] ; S. Dass ; E. Vital [Royaume-Uni] ; P. Emery [Royaume-Uni]	THU0123 Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis
002A30 (2013)	S. Godot [France] ; J. E. Gottenberg [France] ; S. Paternotte ; I. Pane [France] ; B. Combe [France] ; J. Sibilia [France] ; R.-M. Flipo ; T. Schaeverbeke ; P. Ravaud [France] ; E. Toussirot ; F. Berenbaum [France] ; X. Mariette [France] ; D. Wendling ; J. Sellam [France]	THU0122 Safety of surgery in patients with rheumatoid arthritis treated by rituximab in routine care: Data from the french air registry

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Teeft.i -k "Rituximab" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Teeft.i  \
                -Sk "Rituximab" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Teeft.i
   |clé=    Rituximab
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021